CCND1 and neoplasm: In contrast, the in-silico drug candidate identification of scAmpi marked the complete tumor population to be potentially sensitive to palbociclib treatment, based on the over-expression of CCND1 and further supported by the expression of CDK4 (Fig 3C and 3D).